Comparisons of Outcomes With Different Intervals Between Adjunctive Ranibizumab and Photodynamic Therapy for Polypoidal Choroidal Vasculopathy – Corrected Proof

Purpose: To determine the optimal time for administration of intravitreal ranibizumab injections before photodynamic therapy (PDT) as combined therapy to treat polypoidal choroidal vasculopathy (PCV).Design: Retrospective, comparative, interventional case series.Methods: The study included 99 eyes (98 patients) with treatment-naïve subfoveal PCV treated with an intravitreal ranibizumab injection followed by PDT. The combination therapy included 1 ranibizumab injection administered 7 days before PDT (7-day group) or 2 days before PDT (2-day group). All eyes were followed for over 12 months.Results: Intravitreal ranibizumab was administered 7 days before PDT in 59 eyes and 2 days before PDT in 40 eyes. In the 7-day group, the best-corrected visual (Read more...)

Full Story →